Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia

References

• Camitta BM, Thomas ED, Nathan DG et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979;53:504–14.
   PubMed Web of Science ®Google Scholar
• Camitta BM, Thomas ED, Nathan DG et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976;48:63— 70.
   Google Scholar
• Bacigalupo A, Oneto R, Bruno B et al. Current results of bonemarrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol 2000;103:19 — 25.
   Google Scholar
• Storb RK, Blume G, O'Donnell MR et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001;7:39–44.
   Google Scholar
• Castro-Malaspina Childs H, Laver B, Shank B et al. Hyper-fractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia. Int 7 Rad Oncol Biol Phys 1994;29: 847— 54.
   Google Scholar
• Storb R, Etzioni R, Anasetti C et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994;84:941— 9.
   Google Scholar
• Jacobs P, Wood L, Fullard L et al. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transplant 1994;13:763–9.
   PubMed Web of Science ®Google Scholar
• Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34± cell determination by flow cytometry. Hematother 1996;5:213–26.
   PubMedGoogle Scholar
• Hale G, Xia M-Q, Tighe HP et al. The CAMPATH-1 antigen(CDw 52). Tissue Antigens 1990;35:118–27.
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H. Control of graft-versus-host disease andgraft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling trans-plants for malignant diseases. Bone Marrow Transplant 1994;13:597— 611.
   Google Scholar
• Phillips J, Drumm A, Harrison P et al. Manufacture and qualitycontrol of CAMPATH-1 antibodies for clinical trials. Cytotherapy 2001;3:233–42.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A et al. Clinical manifestations ofgraft vs. host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 1974;18:295— 301.
   Google Scholar
• Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer 1990;65:1864–6.
   Google Scholar
• Storb R, Deeg HJ, Farewell V et al. Marrow transplantation forsevere aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986;68:119–25.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Leisenring W, Storb R et al. Long-term outcome aftermarrow transplantation for severe aplastic anemia. Blood 1998;91:3637–45.
   PubMed Web of Science ®Google Scholar
• Min CK, Kim DD, Lee JW et al. Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose. Haematologica 2001;86:303— 10.
   Google Scholar
• Kroger NT, Zabelina H, Renges Wet al. Long-term follow-up ofallogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus anti-thymocyte globulin. Ann Hematol 2002;81:627— 31.
   Google Scholar
• Hale G, Cobbold S, Novitzky N et al. CAMPATH-1 antibodiesin stem cell transplantation. Cytotherapy 2001;3:145— 64.
   Google Scholar
• Novitzky N, Thomas V, Hale G, Waldmann H. CAMPATH-1 antibodies 'in the bag' for haematological malignancies: the Cape Town experience. Cytotherapy 2004;6:172— 81.
   Google Scholar
• Deeg HJ, Amylon ID, Harris RE et al. Marrow transplants fromunrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001;7:208— 15.
   PubMedGoogle Scholar
• Tzeng CH, Chen PM, Fan S et al. CY/TBI-800 as a pretransplant regimen for allogeneic bone marrow transplanta-tion for severe aplastic anemia using HLA-haploidentical family donors. Bone Marrow Transplant 1996;18:273— 7.
   Google Scholar
• Ades L, Mary JY, Robin M et al. Long-term outcome after bonemarrow transplantation for severe aplastic anemia. Blood 2004;103:2490— 7.
   Google Scholar
• Deeg HJ, Socie G, Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996;87:386— 92.
   Google Scholar
• Kolb HJ, Socie G, Duell T et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999;131:738–44.
   Google Scholar
• Eapen M, Ramsay NK, Mertens AC et al. Late outcomes after bone marrow transplant for aplastic anaemia. Br 7 Haematol 2000;111:754–60.
   PubMed Web of Science ®Google Scholar